Folate receptor (FR) is overexpressed in many epithelial cancers and tumor-associated macrophages (TAMs), which enable it to function as an appropriate target for cancer treatment. We have successfully synthesized multifunctional folate-targeted and oxygen/paclitaxel loaded microbubbles (TOPLMBs) for ultrasound (US) mediated delivery for combination therapy in an intraperitoneal ovarian cancer xenograft model. The TOPLMBs target both ovarian cancer cells and TAMs and provide a promising drug delivery strategy for the combination treatment of ovarian cancer and tumor microenvironment.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2isurju
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Greens Blue Flame supplies propane tank installation services and propane delivery in the Houston, TX area. We also offer bulk commercial de...
-
Copyright © 1999-2007 by , Kai Froeb. Permission is granted to copy, distribute and/or modify this document under the terms of the GNU Free ...
-
A Vietnam War Timeline [Note: This timeline is an abbreviated version of the more detailed timeline posted on the Public Broadcasting System...
-
Cutaneous squamous cell carcinoma (cSCC) are amongst the most common cancers with metastatic potential. Specific clinical and pathological “...
-
IZE is a professional association dedicated to expanding the educational impact of zoos and aquariums worldwide, to enhance the understandin...
-
1,001 FREE cover letter examples and samples for consultants, career changers, and job hunters. The FIRST and BEST cover letters on the Inte...
-
The National Booster Club Training Council, Providing Guidance, Education, Training and Support from #AlexandrosSfakianakis via Alexandros...
-
Examples of Money Laundering Investigations - Fiscal Year 2015. The following examples of Money Laundering Investigations are written from p...
-
BibMe Free Bibliography & Citation Maker - MLA, APA, Chicago, Harvard from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inor...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου